One question that needs more attention is why are gay men and lesbians excluded from participating in certain medical studies? A little over a year ago a letter written by three scientists from the Fox Chase Cancer Center in Philadelphia appeared in The New England Journal of Medicine. The letter cited several dozen clinical trials [...]
One of the common side effects reported from chemotherapy with Taxotere is neuropathy. In the trial used to receive FDA approval, TAX 327 which had 332 patients. In that trial the following percentage of men reported incidents of neuropathy: Neuropathy Sensory- Nerve damage causing tingling or pain, usually in feet or hands: Any Grade- 30.4% [...]
The American Society of Clinical Oncologists (ASCO) posted on Wednesday the abstracts from the Genitourinary Conference which is scheduled for February 2-4 in San Francisco, California. Dendreon, the creator of the immunotherapy Provenge for men with metastatic castrate resistant advanced prostate cancer has three very interesting and informative posters which will appear at the conference. [...]
The use of the PSA as a prostate cancer screening tool has been a controversial issue for many years. Within the last year the issue has again come to the forefront of the public awareness, especially because of the recent move of the U.S Preventative Task Force to discourage using the PSA as a screening [...]
Researchers at Ohio State University report that they have developed a new mathematical model for men with advanced prostate cancer who are on androgen deprivation therapy (ADT). This model could guide future treatment decisions for men with advanced prostate cancer, specifically, helping to decide which men would benefit from ADT on an intermittent schedule (IADT). [...]
How to best treat men with a prostate cancer PSA only recurrence (biochemical recurrence) still remains controversial. Hormone therapy (ADT) using a combination of a 5-alpha reductase inhibitor and an antiandrogen without conventional gonadal androgen suppression (where testosterone levels are not suppressed) may allow control of the prostate-specific antigen (PSA) with less morbidity. METHODS: In [...]
From very early on, researchers and doctors have dreamed of using the body’s own immune system to fight cancer. The big question has been why doesn’t the immune system attack the tumor cells that invade healthy tissue? The really good news is that finally science is catching up with this vision. Therapeutic cancer vaccines that [...]
One of the major causes of prostate cancer morbidity and mortality is bone metastases. Currently, when it comes to treating prostate cancer metastases we are very limited in effective therapies that actually prolong survival. Kirschenbaum A, etal (Departments of Urology and Medicine Division of Pulmonary Diseases Division of Endocrinology, Metabolism, and Bone Diseases, Mount Sinai [...]
Again, prostate cancer confusion continues to reign. A recent study reported at the ASTRO (American Society for Radiation Oncology) conference claims that the addition of androgen deprivation therapy (ADT) in men with clinically localized prostate cancer was not associated with increased cardiovascular mortality. According to Jason A. Efstathiou, MD, Ph.D.l, of the Massachusetts General Hospital [...]
A recent article in the journal Cancer reported that there is an association for men being treated for prostate cancer with androgen deprivation therapy (ADT) and a risk of developing blood clots. The article, written by Edhaie et al. analyzed the Surveillance, Epidemiology and End Results (SEER) –Medicare database to identify 154,611 men over the [...]
